Clinical trial

Renal Integrase Study

NCT02351908

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-03-01

PhasePHASE4

Study timeline

Study start (unknown)2015-03-01Date precision: month

Registry last updated2017-06-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIVunresolved

Interventions

Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)DRUG

Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tabletDRUG

Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)DRUG

Sponsors & collaborators

St Stephens Aids Trustlead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02351908 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.